Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NBMX - National Boston Medical (was FGRX) -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey S. Mitchell who wrote (934)	11/17/1998 6:18:00 PM
From: Liberty Capital	Read Replies (1) \| Respond to of 1286

From: J. Allen Greig President of Liberty Capital I wish to clear some of the issues with NBMX. First, the press releases that came out prior to last week were developed and published by the old Fragrance Express management. National Boston Medical understands that there were several errors in those press releases. National Boston Medicals legal staff is currently working to determine if material disclosure requirements were met. National Boston Medical wishes to provide long term shareholder value and they realize that press releases are an important part of this process. However, there are some very simple answers to the ridiculousness that has been posted on some of these boards about NBMX. First, Safeshield is a proprietary product of NBMX. It is wholly owned and distributed by NBMX. The Verta Line distribution rights were acquired by NBMX from Micrillium Laboratories to add to their distribution channels in Canada and the US. NBMX management felt these products would enhance the overall marketing strategy of NBMX while at the same time producing a revenue stream with low overhead. The advantage of having these products manufactured by another company are: 1.no manufacturing overhead and tooling, 2.no distribution costs, 3.no storage costs and finally the added advantage of having a separate fulfillment center to carry out orders. The Verta Vac statement about being uniquly newly developed aside from being bad grammatically is being changed as we speak to something more in line with real English. We hope that investors will see past the former management's hype to the benefits and shareholder concern the new NBMX management team brings to the company. This information is not a solicitation to buy or sell securities. Investors should always consult a registered investment advisor before making any investment decisions. Liberty Capital Group (LCG) picked National Boston ("the Company") due to the tremendous growth potential in the market for antibacterial products. Additionally, LCG feels that the alliances the Company has developed over the last few months will help propel National Boston to a large and sustained revenue stream. Due to the above, LCG has agreed to a contract with National Boston as their financial and public relations firm. LCG's contract is a full one year term and will include fees and cash of between $732,000 - $756,000. Due to huge market potential, LCG has agreed to invest up to $500,000 through an option, with prices scaled from $1.00/sh - $7.00/sh.